Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease.
Aged
Biomarkers
/ blood
China
/ epidemiology
Coronary Angiography
Coronary Artery Disease
/ blood
Female
Humans
Lipoprotein(a)
/ blood
Male
Middle Aged
Myocardial Infarction
/ mortality
Prognosis
Prospective Studies
Recurrence
Risk Assessment
Risk Factors
Stroke
/ mortality
Time Factors
Up-Regulation
Lipoproteins and hyperlipidaemia
cardiac risk factors and prevention
coronary artery disease
Journal
Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
18
01
2020
revised:
01
04
2020
accepted:
09
04
2020
pubmed:
10
5
2020
medline:
29
6
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
Whether lipoprotein(a) (Lp(a)) is a predictor for recurrent cardiovascular events (RCVEs) in patients with coronary artery disease (CAD) has not been established. This study, hence, aimed to examine the potential impact of Lp(a) on RCVEs in a real-world, large cohort of patients with the first cardiovascular event (CVE). In this multicentre, prospective study, 7562 patients with angiography-diagnosed CAD who had experienced a first CVE were consecutively enrolled. Lp(a) concentrations of all subjects were measured at admission and the participants were categorised according to Lp(a) tertiles. All patients were followed-up for the occurrence of RCVEs including cardiovascular death, non-fatal myocardial infarction and stroke. During a mean follow-up of 61.45±19.57 months, 680 (9.0%) RCVEs occurred. The results showed that events group had significantly higher Lp(a) levels than non-events group (20.58 vs 14.95 mg/dL, p<0.001). Kaplan-Meier analysis indicated that Lp(a) tertile 2 (p=0.001) and tertile 3 (p<0.001) groups had significantly lower cumulative event-free survival rates compared with tertile 1 group. Moreover, multivariate Cox regression analysis further revealed that Lp(a) was independently associated with RCVEs risk (HR: 2.01, 95% CI: 1.44 to 2.80, p<0.001). Moreover, adding Lp(a) to the SMART risk score model led to a slight but significant improvement in C-statistic (∆C-statistic: 0.018 (95% CI: 0.011 to 0.034), p=0.002), net reclassification (6.8%, 95% CI: 0.5% to 10.9%, p=0.040) and integrated discrimination (0.3%, 95% CI: 0.1% to 0.7%, p<0.001). Circulating Lp(a) concentration was indeed a useful predictor for the risk of RCVEs in real-world treated patients with CAD, providing additional information concerning the future clinical application of Lp(a).
Identifiants
pubmed: 32381650
pii: heartjnl-2020-316586
doi: 10.1136/heartjnl-2020-316586
doi:
Substances chimiques
Biomarkers
0
LPA protein, human
0
Lipoprotein(a)
0
Types de publication
Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1228-1235Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.